EANS-News: Symrise AG and Probi sign joint research and development agreement

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Subtitle: • Bundling of expertise in developing new product solutions
in the areas of food and beverages, cosmetics, dietary supplements
and pharmaceuticals • Initial focus on oral care applications with
proven health benefits • Expanded know-how for accelerated product
development in dynamic market segments

Company Information

Holzminden, December 20, 2012 (euro adhoc) - The German Symrise AG, a
leading manufacturer of flavors, fragrances, cosmetics and health
ingredients, and the probiotics company Probi AB based in Lund,
Sweden, have signed a joint research and development agreement. In
response to the growing need for turn-key product solutions with
proven health benefits, both companies today announced their plans to
collaborate on innovative projects such as in oral health
applications.

"For Symrise the agreement with Probi is a logical step which, going
forward, allows us to meet the growing demand for functional consumer
health products even better. Both, in established markets as well as
emerging markets, consumers become more and more sensitive to healthy
nutrition and a balanced way of life. The highly complementary
competencies and strategic innovation agendas of Probi and Symrise
will allow us to support our joint customers in their development and
marketing efforts, and to grow at an accelerated pace", stated Dr.
Heinz-Jürgen Bertram, CEO of Symrise AG.

Symrise has expertise in the research, development and manufacturing
of food, beverages, cosmetics and pharmaceutical products and sees
increasing potential in the health benefits of probiotics. The
company combines the ability and the network to perform efficacy
screening with the necessary know-how of applying active ingredients.
Moreover Symrise holds a globally leading position in the area of
oral care.

Probi is a trailblazing company that is highly reputed in the
research, development and manufacturing of probiotics. It sells some
of the most effective gut and immune health probiotics available on
the world market. Expanding into new areas such as oral health will
offer additional growth prospects for the company.

"The globally recognized know-how of Symrise in sensory, active
ingredients and applications combined with Probi's long-standing and
proprietary expertise in patented probiotics will allow us to develop
new consumer products with real health benefits and sensory profiles
without compromises," added Michael Oredsson, CEO of Probi AB.
Symrise AG currently holds a 14.97% minority share of Probi and may
increase this stake in the future. The company is listed on the
NASDAQ OMX Nordic exchange in Stockholm.

About Symrise Symrise is a global supplier of fragrances, flavorings,
cosmetic active ingredients and raw materials as well as functional
ingredients. Its clients include manufacturers of perfumes, cosmetics
and foods, the pharmaceutical industry and producers of nutritional
supplements. Its sales of EUR1.584 billion in 2011 place Symrise
among the top four in the global flavors and fragrances market.
Headquartered in Holzminden, Germany, the Company is represented in
over 35 countries in Europe, Asia, the United States and Latin
America. Symrise works with its clients to develop new ideas and
market-ready concepts for products that form an indispensable part of
everyday life. In doing so, Symrise combines its insights into
consumer trends with cutting-edge technologies, focusing on
innovative trend and lifestyle products that have additional
practical value for the consumer. www.Symrise.com

About Probi Probi is a leading player in the probiotic research and
the development of efficient and well-documented probiotics. The
research areas include: gastrointestinal tracts, immune system,
metabolic syndrome and stress and recovery. Probi's customers are
leading companies in the functional foods and consumer healthcare
business areas. Total income for 2011 was MSEK 95.0. Probi's share is
listed on the Nasdaq OMX Stockholm, Small Cap. Probi has
approximately 4,500 shareholders. www.probi.com.

Contact:
Symrise AG
Bernhard Kott

Phone: +49 (0)5531 90-1721
E-mail: bernhard.kott@symrise.com

Probi AG

Michael Oredsson
Phone: +46 46 286 23
E-mail: michael.oredsson@probi.se

Further inquiry note:
Pressekontakt
Bernhard Kott
Tel. +49 (0)5531 90-1721
bernhard.kott@symrise.com
Phone: +46 46 286 23

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: Symrise AG
Mühlenfeldstraße 1
D-37603 Holzminden
phone: +49 (0) 5531/90-0
FAX: +49 (0) 5531/90-1649
mail: ir@symrise.com
WWW: http://www.symrise.com
sector: Chemicals
ISIN: DE000SYM9999
indexes: MDAX
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
Stuttgart, regulated dealing/prime standard: Frankfurt
language: English